NCT06383533View on ClinicalTrials.gov

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

May 1, 2025

Study Completion Date

December 31, 2025

Conditions
Bile Duct Adenocarcinoma Non-ResectableHER2 Gene Mutation
Interventions
DRUG

Disitamab Vedotin Plus Cadonilimab

Disitamab Vedotin: 2.0mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Cardonilimab: 6mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle.

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER